Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06544707 · ClinicalTrials.gov registry record · Phase 3
A Study Designed to Evaluate Tear Production
A Phase 3 study of Dry Eye Disease, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 81
- Enrollment target
- 1
- Study location
NCT06544707: Completed Phase 3 study of Dry Eye Disease, sponsored by Alcon Research.
NCT06544707 is a Phase 3 study of Dry Eye Disease that has completed, run by Alcon Research. The registered enrollment target is 81 participants, below the 253-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06544707, a Phase 3 study of Dry Eye Disease, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate tear production following acute administration of AR-15512 ophthalmic solution 0.003% (0.003% AR-15512) in subjects with dry eye disease (DED).
Primary Outcome
TMH (the distance between the line of reflection along the top of the tear prism to the edge of the central lower eyelid) was measured pre-instillation and post-instillation in micrometers using optical coherence tomography (OCT), a non-invasive imaging test that uses light waves to take cross-section pictures of the eye. A normal TMH range falls between 200 and 400 micrometers. Measurements below this range may indicate dry eye disease. A positive change value indicates an improvement. One eye
Conditions Studied
Interventions
- DRUG 0.003% AR-15512 ophthalmic solution
Study Locations (1)
California
- Eye Research Foundation - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2024-10-15 |
| Est. Completion | 2025-01-30 |
| Phase | Phase 3 |
What the finished NCT06544707 record still lists
NCT06544707 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 253-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 1 intervention - of which 0.003% AR-15512 ophthalmic solution is the first listed.
NCT06544707 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06544707 about?
NCT06544707 is a clinical study titled "A Study Designed to Evaluate Tear Production". The purpose of this study is to evaluate tear production following acute administration of AR-15512 ophthalmic solution 0.003% (0.003% AR-15512) in subjects with dry eye disease (DED).
What is the current status of trial NCT06544707?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 81 participants. The study started on 2024-10-15. Estimated completion is 2025-01-30.
What conditions does trial NCT06544707 study?
This clinical trial studies the following conditions: Dry Eye Disease.
What interventions are being tested in trial NCT06544707?
The interventions under investigation include: 0.003% AR-15512 ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT06544707?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06544707 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06544707's enrollment target sits among peer trials
81 27th of 33 higher than 7 of 33 other Dry Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
RECRUITING · Phase 3
-
A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
COMPLETED · Phase 3
-
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
COMPLETED · Phase 3
-
ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
COMPLETED · Phase 3
-
A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI